A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2026

Conditions
Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (NVAMD)BRVO - Branch Retinal Vein Occlusion
Interventions
DRUG

EYE201

EYE201 solution for intravitreal administration

Trial Locations (27)

21740

RECRUITING

Hagerstown, Maryland, Hagerstown

27587

RECRUITING

Wake Forest, NC, Wake Forest

28803

RECRUITING

Asheville, NC, Asheville

29169

RECRUITING

West Columbia, South Carolina, West Columbia

33064

RECRUITING

Deerfield Beach, FL, Deerfield Beach

37203

RECRUITING

Nashville, Tennessee, Nashville

37922

RECRUITING

Knoxville, TN, Knoxville

38138

RECRUITING

Germantown, Tennessee, Germantown

39110

RECRUITING

Madison, Mississippi, Madison

60439

RECRUITING

Lemont, IL, Lemont

75075

RECRUITING

Plano, TX, Plano

75231

RECRUITING

Dallas, Texas, Dallas

77384

RECRUITING

Woodlands, Texas, The Woodlands

77401

RECRUITING

Bellaire, Texas, Bellaire

RECRUITING

Bellaire, TX, Bellaire

78240

RECRUITING

San Antonio, Texas, San Antonio

78681

RECRUITING

Round Rock, TX, Round Rock

78705

RECRUITING

Austin, Texas, Austin

79106

RECRUITING

Amarillo, Texas, Amarillo

79606

RECRUITING

Abilene, Texas, Abilene

85255

RECRUITING

Scottsdale, Arizona, Scottsdale

94040

RECRUITING

Mountain View, California, Mountain View

95356

RECRUITING

Modesto, CA, Modesto

95825

RECRUITING

Sacramento, CA, Sacramento

95841

RECRUITING

Sacramento, California, Sacramento

07003

RECRUITING

Bloomfield, New Jersey, Bloomfield

00612

RECRUITING

Arecibo, PR, Arecibo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EyeBiotech Ltd.

INDUSTRY

NCT06664502 - A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter